Monthly Archives: April 2016
- Cover story
- Economy outlook
- Financial strategy
- Legal spotlight
- Point of interest
- Remark from editor
“Chinese Quality” and “Chinese Standards” stand the strong earthquake test in Ecuador.
Ecuador took place 7.8-magnitude strong earthquake on April 14, 2016 at local time. The water conservancy project, road and bridge and other civil buildings by the Chinese technological equipment and Chinese enterprises stood solid and unshakable, defying this strong earthquake with their excellent quality. “Chinese quality” and “Chinese standards” passed the test of the strong earthquake and played a positive role in the rescue work, which won the praise of the people of Ecuador. Continue reading
The Institute of South South Cooperation and Development of Peking University was launched on the 29th of April to fulfill the pledges Chinese leaders made in the UN. Continue reading
Taiwanese government’s objectives for digitizing financial services are to develop the financial technology (FinTech) industry, gain firmer control over the domestic economy, and provide convenient and innovative digital services for the public, Premier Chang San-cheng said. Continue reading
International surveys and domestic polls alike testify that the government’s anti-corruption efforts in recent years have produced overall improvement, Premier Chang San-cheng stated on the 28th of April while presiding over the central anti-corruption committee’s 16th meeting. Continue reading
Taiwanese Premier Chang San-cheng on the 30th of April attended the opening ceremony for New Taipei City’s 2016 Hakka Tung Blossom Festival, where he invited the public to come out and enjoy Taiwan’s natural beauty.
Mr. Zhong Shan, a Han Chinese, is a native of Shangyu County, Zhejiang Province. He was born in October 1955, started his career in July 1972 and joined the CPC in June 1974. Mr. Zhong holds a PhD in economics from Zhejiang University and is a Senior Economist. Continue reading
Recently in Taiwan, a highly valued, in terms of stock prices, biotech startup, Obipharma, stirred up turmoil after unblinding one of its clinical trials. The clinical trial is about a cancer vaccine and was touted to be quite promising all along. As what usually happens in clinical trials, the results fail to live up to the company’s and the general public’s high expectation. Needless to say, the final results of this trial fell short of the primary end point. No surprise at all, its stock prices plummeted. Continue reading